Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0033687 (
proteinuria
)
24,015
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Preeclampsia is a common, pregnancy-specific vascular disorder characterised by hypertension and
proteinuria
. A recent report suggested association of the
STOX1
gene on chromosome 10q22.1 with preeclampsia in the Dutch population. Here, we present a comprehensive assessment of
STOX1
as a candidate gene for preeclampsia in the Finnish population by re-examining our previous genetic linkage analysis results for both chromosome 10 and paralogous loci, by genotyping representative markers in a nationwide data set, and by studying
STOX1
expression in placentas from preeclamptic and uncomplicated pregnancies. In conclusion, we are unable to validate
STOX1
as a common preeclampsia susceptibility gene.
...
PMID:Evaluation of STOX1 as a preeclampsia candidate gene in a population-wide sample. 1729 Feb 74
Preeclampsia is a common disease of pregnancy, characterized by high blood pressure and
proteinuria
appearing from the second trimester of gestation. Preeclampsia has been shown to have a strong genetic component. In 2005 a positional cloning project led to the discovery of the
STOX1
transcription factor, and mutations of this gene were proposed as causal for preeclampsia in Dutch families. Despite the publication of three contradictory studies, we have shown by analyzing the functional effects of
STOX1
that its overexpression in choriocarcinoma cells recapitulates several transcriptomic aspects of preeclampsia. In this review, the current literature is analyzed to evaluate the possible involvement of
STOX1
in the pathogenesis of this disease. While preeclampsia obviously cannot be considered as a disease caused by mutation in a single gene, we argue that
STOX1
may be at the center of common pathways leading to preeclampsia.
...
PMID:Re-evaluation of the role of STOX1 transcription factor in placental development and preeclampsia. 1957 9
Preeclampsia (PE) is a common human-specific pregnancy disorder defined by hypertension and
proteinuria
during gestation and responsible for maternal and fetal morbimortality.
STOX1
, encoding a transcription factor, was the first gene associated with PE as identified by positional cloning approaches. Its overexpression in choriocarcinoma cells mimics the transcriptional consequences of PE in the human placenta. Here, we created transgenic mouse strains overexpressing human
STOX1
. Wild-type female mice crossed with transgenic male mice reproduce accurately the symptoms of severe PE: gestational hypertension,
proteinuria
, and elevated plasma levels of soluble fms-like tyrosine kinase 1 and soluble endoglin. Placental and kidney histology were altered. Symptoms were prevented or alleviated by aspirin treatment.
STOX1
-overexpressing mice constitute a unique model for studying PE, allow testing therapeutic approaches, and assessing the long-term effects of the preeclamptic syndrome.
...
PMID:Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment. 2335 80
The familial forms of early onset pre-eclampsia and related syndromes (HELLP) present with hypertension and
proteinuria
in the mother and growth restriction of the fetus. Genetically, these clinically similar entities are caused by different founder-dependent, placentally-expressed paralogous genes. All susceptibility genes (
STOX1
, lincHELLP, INO80B) identified so far are master control genes that regulate an essential trophoblast differentiation pathway, but act at different entry points. Many genes remain to be identified. Here we demonstrate that a long non-coding RNA (lncRNA) within intron 3 of the STOX2 gene on 4q35.1 acts as a permissive cis-acting regulator of alternative splicing of STOX2. When this lncRNA is mutated or absent, an alternative exon (3B) of STOX2 is included. This introduces a stop codon resulting in the deletion of a highly conserved domain of 64 amino acids in the C-terminal of the STOX2 protein. A mutation present within a regulatory region within intron 1 of STOX2 has the same effect after blocking with CRISPR technology: transcripts with exon 3B are upregulated. This proces appears related to transcriptional control by a chromatin-splicing adaptor complex as described for FGFR2. For STOX2, CHD5, coding for a chromodomain helicase DNA binding protein, qualifies as the chromatin modifier in this process.
...
PMID:Noncoding RNA-regulated gain-of-function of STOX2 in Finnish pre-eclamptic families. 2755 60